Navigation Links
CryoLife Posts Record Annual Revenues of $116.6 Million
Date:2/17/2011

ck at average prices of $5.70 and $5.56, respectively, resulting in aggregate purchases of $1.5 million and $5.8 million, respectively.

Medafor UpdateOn September 27, 2010, Medafor sent CryoLife a letter stating that Medafor was "fully, finally, and immediately terminating" the Exclusive Distribution Agreement ("EDA").  CryoLife believes this termination was wrongful.  CryoLife expects to continue to sell HemoStase until late March 2011.  CryoLife is challenging the validity of Medafor's termination of the EDA and pursuing its rights and remedies in court.  Medafor has asserted counterclaims against CryoLife.  Discovery proceedings in the litigation have commenced and the Company believes that a trial would not likely occur before 2012.

2011 Financial Guidance The Company is providing its guidance for the full year of 2011.  The Company expects total revenues for the full year of 2011 to be between $120.0 million and $126.0 million, which includes revenues of between $500,000 and $1.0 million related to the use of funds received from the U.S. Department of Defense in connection with the development of BioFoam.  The Company expects tissue processing revenues to increase between mid-single and low-double digits on a percentage basis in 2011 compared to 2010, BioGlue and BioFoam revenues to increase in mid-single digits on a percentage basis in 2011 compared to 2010, with revenues from powdered hemostats, including HemoStase and PerClot, to be between $4.0 million and $6.0 million.  Research and development expenses are expected to be between $10.0 million and $12.0 million in 2011.  The Company expects earnings per share of between $0.26 and $0.30 in 2011.

The Company's financial guidance for the full year of fiscal 2011 is subject to the risks described below in the last paragraph of this press release.

Webcast and Conference Call InformationThe Company will hold a teleconference call a
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
2. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
4. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
5. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
6. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
7. CryoLife Provides Initial 2010 Financial Guidance
8. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
9. CryoLife to Present at Upcoming Investor Conferences in New York
10. CryoLife Reports Record Quarterly Revenues of $28.2 Million
11. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ATLANTA , Jan. 23, 2015 More than a ... a quarter of those with private insurance, filled a prescription ... to a report in this week,s Morbidity and Mortality Weekly ... health care providers to treat moderate to severe pain.  They ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects ... ... Population, SAN FRANCISCO, June 7 ... type 2 diabetes,that were enrolled in a Phase III study showed ...
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
Cached Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... Glendale, AZ (PRWEB) January 22, 2015 Padre ... a long supporter of Pro Player Health Alliance ... with Padre Murphy's in getting everyone, including NFL greats, treated ... one of the leading groups supporting the cause in the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Broad Institute have found strikingly high levels of a ... contribute to the disease and potentially be a key ... published online in the journal Genome Research, ... of Fusobacterium cells in nine colorectal tumor samples. ...
... COLUMBIA, Mo. It is well known that eating ... alcohol consumption is another well-known unhealthy habit of this ... Missouri shows that when college students combine these two ... is a new term coined by the media to ...
... MONDAY, Oct. 17 (HealthDay News) -- The public health price ... almost $2 a drink, a new government report shows. ... this country," CDC Director Dr. Thomas R. Frieden said during ... The economic toll of problem drinking affects everybody through lost ...
... The use of surgery to treat early-stage laryngeal cancer (cancer ... and chemotherapy in combination with radiation therapy is being used ... disease, according to a report in the October issue of ... one of the JAMA/Archives journals. Cancer of the larynx, ...
... By Alan Mozes HealthDay Reporter , MONDAY, Oct. ... around the notion that "you are what you eat." ... the strength and quantity of sperm. The observation stems ... the American Society for Reproductive Medicine annual meeting in Orlando, ...
... stage of cancer favour aggressive chemotherapy over supportive care ... CMAJ (Canadian Medical Association Journal) (pre-embargo link only) ... cause of death for children aged 5 to 14 ... will be cured, parents and health care professionals must ...
Cached Medicine News:Health News:Researchers find possible link between bacterium and colon cancer 2Health News:'Drunkorexia:' A recipe for disaster 2Health News:Excessive Drinking Costs U.S. Billions, CDC Reports 2Health News:More surgery in early-stage laryngeal cancer treatment; more chemoradiation for advanced-stage 2Health News:Healthier Diet, Stronger Sperm? 2Health News:Healthier Diet, Stronger Sperm? 3Health News:Pediatric cancer and palliative care: parental preferences compared with health-care professionals 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: